$875M. 3 months ago - Business . Director. Atara Biotherapeutics, Inc. is a privately-held drug development company with a focus on innovative therapies for patients with debilitating diseases. Fujifilm Completes Acquisition of a Dedicated Cell Therapy Manufacturing Facility from Atara Biotherapeutics, Inc. FUJIFILM Corporation today announced that it has completed the acquisition of a. TOKYO - FUJIFILM Corporation (President and CEO, Representative Director: Teiichi Goto) today announced that it has completed the acquisition of a dedicated cell therapy manufacturing facility from Atara Biotherapeutics, Inc. (Nasdaq: ATRA) for USD 100 million.The facility located in Thousand Oaks, California, will be operated as part of FUJIFILM Diosynth Biotechnologies' global network . The all time high for this statistics is 17. | April 5, 2022 Atara Biotherapeutics Inc (NASDAQ:ATRA) was in 22 hedge funds' portfolios at the end of the second quarter of 2020. She serves as Chairman of AnaptysBio and as a Director at Millendo Therapeutics. . Molecularly targeted product candidates include PINTA 745, STM 434 and ATA 842, members of the TGF-beta . SVP and Head of Business Development and Corporate Strategy at Atara Biotherapeutics . Atara Biotherapeutics, Inc. is a pioneer in T-cell immunotherapy leveraging its novel allogeneic EBV T-cell platform to develop transformative therapies for patients with serious diseases . . TOKYO, April 04, 2022 (GLOBE NEWSWIRE) -- FUJIFILM Corporation (President and CEO, Representative Director: Teiichi Goto) today announced that it has. We are considered a leading off-the-shelf T-cell immunotherapy . 1. Information on acquisition, funding, investors, and executives for Atara Biotherapeutics (T-Cell Operations and Manufacturing Facility in Thousand Oaks, California). Company Description: Atara Biotherapeutics, Inc. is located in Thousand Oaks, CA, United States and is part of the Pharmaceutical and Medicine Manufacturing Industry. In connection with the Quarterly Report of Atara Biotherapeutics, Inc. . Director. Carol G Gallagher, Pharm.D. Over the last five trading days since the potential acquisition was announced, bluebird is up 17.5%, ZIOPHARM Oncology is up 15%, and Atara Biotherapeutics is up 11% relative to the IBB which is . About Atara Biotherapeutics, Inc. Atara Biotherapeutics, Inc. (@Atarabio) is a pioneer in T-cell immunotherapy leveraging its novel allogeneic EBV T-cell platform to develop transformative . Delighted to announce the planned acquisition of the Atara T-Cell Operations and Manufacturing facility in . Atara Biotherapeutics and Crispr Therapeutics stand out as strong takeover candidates. Atara Biotherapeutics, Inc. is a leading allogeneic T-cell immunotherapy company pioneering the development of transformative therapies for patients with serious diseases including solid tumors, hematologic cancers and autoimmune diseases. Company profile. The research of Atara and its family of companies is based on groundbreaking discoveries regarding the ability of activin, myostatin and other biological targets to change the course of disease . This means the bullish number of . $9.40. IMS shall have the meaning set forth in the recitals hereto. (-2.29%) -$0.22. Responsible for acquisition and coordinating installation of new lab assets. Atara Biotherapeutics to Announce Fourth Quarter and Full Year 2021 Financial Results on Monday, February 28, 2022. Atara Biotherapeutics is a leading off-the-shelf, allogeneic T-cell immunotherapy company developing novel treatments for patients with cancer, autoimmune, and viral diseases. FUJIFILM (FUJIY) is acquiring a cell therapy manufacturing facility from Atara Biotherapeutics (ATRA) for $100M.The Thousand Oaks, Calif.-based facility has the flexibility to produce. A = Grant, award or other acquisition pursuant to Rule 16b-3(d) C = Conversion of derivative security . Sep 2019 - Mar 20222 years 7 months. Dr. Dupont owns 163,006 shares of Atara Biotherapeutics stock worth more than $841,111 as of May 19th. Los Angeles Metropolitan Area. SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)-- Atara Biotherapeutics, Inc., (Nasdaq: ATRA), a leader in T-cell immunotherapy, leveraging its novel allogeneic EBV T-cell platform to develop transformative therapies for patients with cancer and autoimmune diseases, today announced FUJIFILM Diosynth Biotechnologies, a subsidiary of FUJIFILM Corporation (Fujifilm), has completed the acquisition of . TOKYO, April 04, 2022 (GLOBE NEWSWIRE) -- FUJIFILM Corporation (President and CEO, Representative Director: Teiichi Goto) today announced that it has completed the acquisition of a dedicated cell therapy manufacturing facility from Atara Biotherapeutics, Inc. (NASDAQ:ATRA) for USD 100 million.The facility located in Thousand Oaks, California, will be operated as part of FUJIFILM Diosynth . About Atara Biotherapeutics, Inc. Atara Biotherapeutics, Inc. is a pioneer in T-cell immunotherapy leveraging its novel allogeneic EBV T-cell platform to develop transformative therapies for . FUJIFILM (FUJIY) is acquiring a cell therapy manufacturing facility from Atara Biotherapeutics (ATRA) for $100M.The Thousand Oaks, Calif.-based facility has the flexibility to produce. Leveraging our novel allogeneic EBV T-cell platform, Atara intends to deliver treatments to patients with . Atara Biotherapeutics, Inc. (), a leader in T-cell immunotherapy, leveraging its novel allogeneic EBV T-cell platform to develop transformative therapies for patients with cancer and autoimmune diseases, today reported the grant of an aggregate of 115,059 restricted stock units of Atara s common stock to 13 newly hired employees and stock options to purchase an aggregate of 118,745 shares of . On April 4, 2022 Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leader in T-cell immunotherapy, leveraging its novel allogeneic EBV T-cell platform to develop transformative therapies for patients with cancer and autoimmune diseases, reported FUJIFILM Diosynth Biotechnologies, a subsidiary of FUJIFILM Corporation (Fujifilm), has completed the acquisition of Atara's cell therapy manufacturing . Fujifilm Completes Acquisition of a Dedicated Cell Therapy Manufacturing Facility from Atara Biotherapeutics, Inc. FUJIFILM Corporation today announced that it has completed the acquisition of a. More about Atara Bio. (Fujifilm), has completed the acquisition . About Atara Biotherapeutics, Inc. Atara Biotherapeutics, Inc. is a pioneer in T-cell immunotherapy leveraging its novel allogeneic EBV T-cell platform to develop transformative therapies for . 1w. ATRA: Atara Biotherapeutics . Manher (AJ) Joshi was appointed to the role of Atara Biotherapeutics' Chief Medical Officer in September 2018. Date 1/26/2022 5:00:51 PM Goto) today announced that it has entered into an agreement to acquire a cell therapy manufacturing facility from Atara Biotherapeutics, Inc. (Nasdaq: ATRA) for USD 100 million . Atara Biotherapeutics, Inc. is a pioneer in T-cell immunotherapy leveraging its novel allogeneic EBV T-cell platform to develop transformative therapies for patients with serious diseases including solid tumors, hematologic cancers and autoimmune disease. This partnership and acquisition was first announced in January 2022. . Atara Bio's programs include molecularly targeted product candidates and T-cell product candidates. Atara Biotherapeutics has reached an . Mr. Koppikar owns 161,369 shares of Atara Biotherapeutics stock worth more than $806,845 as of May 12th. About Atara Biotherapeutics, Inc. Atara Biotherapeutics, Inc. (@Atarabio) is a pioneer in T-cell immunotherapy leveraging its novel allogeneic EBV T-cell platform to develop transformative . Use the PitchBook Platform to explore the full profile. 650-278-8930. www.atarabio.com. This net worth evaluation does not reflect any other assets that Mr. Koppikar may own. Atara Biotherapeutics, Inc. is a pioneer in T-cell immunotherapy leveraging its novel allogeneic EBV T-cell platform to develop transformative therapies for patients with serious diseases . FUJIFILM Corporation (President and CEO, Representative Director: Teiichi Goto) today announced that it has entered into an agreement to acquire a cell therapy manufacturing facility from Atara Biotherapeutics, Inc. (Nasdaq: ATRA) for USD 100 million. Alex works at Atara Biotherapeutics as Sr. Director, Talent Acquisition. Thanks for . FRANKFURT (Reuters) - Bayer AG has struck a deal with Atara Biotherapeutics to jointly work on Atara's CAR-T cell anti-tumour treatments, as the German group firms up its commitment . She recently joined the life sciences practice of New Enterprise Associates as a Partner. SOUTH SAN FRANCISCO, Calif. Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leader in T-cell immunotherapy, leveraging its novel allogeneic EBV T-cell platform to develop transformative therapies for patients with cancer and autoimmune diseases, today announced FUJIFILM Diosynth Biotechnologies, a subsidiary of FUJIFILM Corporation (Fujifilm), has completed the . Item 2.01 Completion of Acquisition or Disposal of Assets. Atara Biotherapeutics, Inc. is a biopharmaceutical company focused on developing innovative therapies for patients with debilitating diseases. Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leader in T-cell immunotherapy, leveraging its novel allogeneic EBV T-cell platform to develop transformative therapies for patients with cancer and . Advisor Insights; Personal Finance; Market Volatility; Retirement Planning; Start Investing; Save for College; Best Investments; See All This net worth estimate does not reflect any other assets that Dr. Dupont may own. He joined Atara in August 2016, initially serving as Senior Vice President, Global Medical Affairs. Atara is providing this information in accordance with Nasdaq Listing Rule 5635 (c) (4). Atara Biotherapeutics Announces the Completion of the Acquisition of Its Cell Therapy Manufacturing Facility & Commencement of LongTerm Strategic Partnership with . Alex Yoo. From 2008-2011, Carol was the president . Atara Biotherapeutics celebrated AAPI Heritage Month by getting to know a few of our Atarians' heritage, culture and their favorite recipes to Asian cuisine and drinks! Alex is based out of Los Angeles County, California, United States and works in the Biotechnology industry. SOUTH SAN FRANCISCO, Calif.-- (BUSINESS WIRE)--Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leader in T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr virus (EBV) T-cell platform to de. SOUTH SAN FRANCISCO, Calif., April 04, 2022--Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leader in T-cell immunotherapy, leveraging its novel allogeneic EBV T-cell platform to develop . The estimated net worth of Utpal Koppikar is at least $806,845.00 as of August 17th, 2021. About Atara Biotherapeutics, Inc. Atara Biotherapeutics, Inc. (@Atarabio) is a pioneer in T-cell immunotherapy leveraging its novel allogeneic EBV T-cell platform to develop transformative . The Company is a developer of T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr virus (EBV) T-cell platform to develop transformative therapies for patients with serious diseases, including solid tumors, hematologic cancers, and autoimmune disease. 611 GATEWAY BLVD, SUITE 900, SOUTH SAN FRANCISCO, CA 94080. Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leader in T-cell immunotherapy, leveraging its novel allogeneic EBV T-cell platform to develop transformative therapies for patients with cancer and autoimmune diseases, today announced FUJIFILM Diosynth Biotechnologies, a subsidiary of FUJIFILM Corporation (Fujifilm), has completed the acquisition of Atara's cell therapy manufacturing facility . The facility located in Thousand Oaks, California, will be operated as part of FUJIFILM Diosynth Biotechnologies . SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)-- Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leader in T-cell immunotherapy, leveraging its novel allogeneic EBV T-cell platform to develop transformative therapies for patients with cancer and autoimmune diseases, today announced that it has entered into a long term strategic agreement with FUJIFILM Diosynth Biotechnologies (FDB), a subsidiary . "We are thrilled that through this acquisition we will add approximately 140 talented staff from Atara's cell therapy manufacturing facility to the . About Atara Biotherapeutics, Inc. Atara Biotherapeutics, Inc. is a pioneer in T-cell immunotherapy leveraging its novel allogeneic EBV T-cell platform to develop transformative therapies for patients with serious diseases including solid tumors, hematologic cancers and autoimmune disease.With our lead program in Phase 3 clinical development and currently under review to support registration in . Biopharmaceutical executive Charlene Banard has joined Atara Biotherapeutics Inc. as chief technical officer. Facilitate sending and receiving precious biological samples. SOUTH SAN FRANCISCO, Calif., April 04, 2022--Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leader in T-cell immunotherapy, leveraging its novel allogeneic EBV T-cell platform to develop transformative therapies for patients with cancer and autoimmune diseases, today announced FUJIFILM Diosynth Biotechnologies, a subsidiary of FUJIFILM Corporation (Fujifilm), has completed the acquisition of . Atara Biotherapeutics, Inc. has 4 employees at this location. Senior Manager Talent Acquisition. SOUTH SAN FRANCISCO, Calif., May 05, 2022--Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leader in T-cell immunotherapy, leveraging its novel allogeneic EBV T-cell platform to develop transformative therapies for patients with cancer and autoimmune diseases, today reported financial results for the first quarter 2022, recent business highlights and key upcoming catalysts.